Latest Commercialization News

Viva Energy delivered a slight increase in sales volumes for 4Q2024 and a record Commercial & Industrial segment performance, despite a disruptive refinery outage and challenging retail conditions. The company also secured key approvals for its Liberty Convenience acquisition, aiming for completion by March 2025.

Sprintex has locked in A$30 million in distribution agreements across the UK, Turkiye, and India, while advancing its innovative G25 Jet Blower launch, signaling a strong growth trajectory in energy-efficient technologies.

BrainChip Holdings reports a US$20 million cash balance and key defense contracts in its December 2024 quarterly update, underscoring its growing foothold in neuromorphic AI commercialization.

Dimerix Limited has inked a lucrative licensing agreement with Fuso Pharmaceutical for its kidney disease drug DMX-200 in Japan, while completing recruitment for its pivotal Phase 3 ACTION3 trial.

Vection Technologies has reported a milestone positive net cash flow in its traditionally weak quarter, driven by a 60% half-on-half revenue surge and strategic acquisition integration.

Gold Road Resources projects a significant production increase at Gruyere in 2025 and has initiated underground drilling to potentially extend mine life beyond 2032.

Terrain Minerals has launched Stage Two of its RC drilling campaign at the Wildflower Gold Project, expanding its exploration with two new targets and reinforcing optimism for a significant gold discovery. Concurrently, the Lort River Project drilling has intersected key bedrock conductors, marking progress in nickel-copper exploration.

First Graphene has secured key patents for its Kainos Technology in Australia and Korea, positioning itself at the forefront of producing graphite, graphene, and hydrogen from petroleum waste. This milestone aligns with growing global demand for critical minerals essential to the energy transition.

Telix Pharmaceuticals has finalized its acquisition of RLS (USA) Inc., significantly expanding its radiopharmaceutical footprint across the United States with a network of over 30 radiopharmacies.

Zelira Therapeutics has received a fourth funding tranche, bringing total investment to US$3.25 million to support FDA clinical trials of its HOPE® 1 cannabinoid medicine targeting irritability in autism spectrum disorder and Phelan-McDermid Syndrome.

Swift Networks reports steady cash flow and contract wins in mining and aged care, while unveiling a new feature to capitalize on upcoming aged care legislation.

Argosy Minerals has reported significant progress on its flagship Rincon Lithium Project, including an upgraded mineral resource estimate and advancing engineering and feasibility studies toward a 12,000tpa lithium carbonate operation.